期刊
CURRENT OPINION IN PHARMACOLOGY
卷 13, 期 4, 页码 511-518出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2013.05.018
关键词
-
资金
- Associazione Italiana per la Ricerca sul Cancro (AIRC)
- Associazione Italiana per la Ricerca sul Cancro (FIRC)
Despite the initial skepticism, targeted therapies represent a new perspective in the treatment of cancer. Tyrosine kinases, and in particular receptor tyrosine kinases (RTKs), are considered ideal targets for this type of therapy. MET, the tyrosine kinase receptor for the Hepatocyte Growth Factor (HGF), has recently become a very interesting and studied target in oncology. In this review we discuss firstly 'why' the MET/HGF pathway can be considered a target in human tumors; secondly 'where' MET/HGF inhibition can be useful in cancer treatment and finally 'how' MET and HGF can be inhibited using either monoclonal antibodies or tyrosine kinase inhibitors. We also highlight some questions in the anti-MET/HGF targeted therapy field that are still waiting for an answer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据